Followers | 86 |
Posts | 6183 |
Boards Moderated | 0 |
Alias Born | 05/27/2009 |
Tuesday, January 04, 2022 9:21:21 AM
-- 1/4/2022: SNGX Dusquetide previously demonstrated benefits in reducing the duration of severe oral mucositis (SOM) in a Phase 2 clinical trial and reduction in SOM rates in the per protocol population in a Phase 3 study. In addition to the reduction of severe oral mucositis, an acceleration in the clearance of tumor response and an increase in overall survival were also observed in the Phase 2 clinical study as an ancillary benefit to treating oral mucositis in patients receiving chemo-radiation for their head and neck cancer (HNC). https://finance.yahoo.com/news/dusquetide-demonstrates-positive-anti-tumor-123000840.html
-- Nov 12, 2021 - Soligenix, Inc., a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the quarter ended September 30, 2021. Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix stated, "There continues to be a great deal of activity across our Specialized BioTherapeutics and Public Health Solutions business segments. We continue to work diligently to prepare the new drug application (NDA) for HyBryte(TM) (SGX301 or synthetic hypericin) following the positive pivotal Phase 3 FLASH (Fluorescent Light Activated Synthetic Hypericin) study in cutaneous T-cell lymphoma (CTCL). The Office of Orphan Products Development of the United States (U.S.) Food and Drug Administration (FDA) granted orphan drug designation to the active ingredient hypericin for the treatment of T-cell lymphoma, expanding the treatment population beyond CTCL. Dr. Schaber continued, "With approximately $29 million in cash, not including our non-dilutive government funding, we anticipate having the necessary capital to achieve our upcoming milestones, including NDA filing and expansion into psoriasis with the conduct of the Phase 2a clinical trial. We are also continuing to actively assess various strategic options, including but not limited to, partnership and merger and acquisition opportunities."
-- November 8, 2021, SNGX announced it had been granted a Pediatric Investigation Plan (PIP) product-specific waiver in the United Kingdom from the Medicines and Healthcare products Regulatory Agency for HyBryte(TM) in the treatment of CTCL.
-- November 4, 2021, SNGX announced the publication of pre-clinical immunogenicity studies for RiVax(R) (heat stable ricin toxin vaccine) demonstrating enduring protection for at least 12 months
post-vaccination. The article titled "Durable Immunity to Ricin Toxin
Elicited by a Thermostable, Lyophilized Subunit Vaccine" has been
accepted for publication in the journal mSphere.
-- September 28, 2021, SNGX announced the publication of
pre-clinical immunogenicity studies for CiVax(TM) demonstrating durable
broad-spectrum neutralizing antibody responses, including against the
Beta, Gamma and Delta variants of concern. The article, titled "Protein
Vaccine Induces a Durable, More Broadly Neutralizing Antibody Response in Macaques than Natural Infection with SARS-CoV-2 P.1", has been posted as an accelerated preprint on bioRxiv.
-- September 16, 2021, SNGX announced that following the
validation of synthetic hypericin's biologic activity in the positive
pivotal Phase 3 FLASH study in CTCL, as well as PoC demonstrated in a
small Phase 1/2 pilot study in mild-to-moderate psoriasis patients, the
Company will be expanding this novel therapy under the research name
SGX302 into psoriasis, a large and underserved market affecting between
60-125 million people worldwide.
-- September 14, 2021: 9/14: Soligenix Develops Groundbreaking Vaccine Platform to Target Future Pandemics. Soligenix Develops Groundbreaking Vaccine Platform to Target Future Pandemics. "The COVID-19 pandemic has already cost the United States an estimated $16 trillion in lost economic output, and has resulted in the loss of over 600,000 lives. At the end of last month, the country reached the dubious milestone of 39 million diagnosed cases of COVID, however, researchers have estimated a further 4.8 undiagnosed cases per diagnosis, bringing the nation's total number of infections closer to 200 million.
-- On September 9, 2021, SNGX announced that the Office of Orphan Products Development of the U.S. FDA had granted orphan drug designation to the active ingredient hypericin for the treatment of T-cell lymphoma, extending the target population beyond CTCL as previously granted.
-- On August 23, 2021, SNGX announced a publication describing the formulation of single-vial platform presentations of monovalent (single antigen), bivalent (two antigens) and trivalent (three antigens)
combinations of filovirus vaccine candidates. In collaboration with
University of Hawai i at M noa (UHM) and University of Colorado
co-authors, the manuscript titled "Single-Vial Filovirus Glycoprotein
Vaccines: Biophysical Characteristics and Immunogenicity after
Co-lyophilization with Adjuvant", has been published in Vaccine. To read
the publication, please click here.
-- August 18, 2021, SNGX announced positive data demonstrating the efficacy of multiple filovirus vaccine candidates in NHPs, including thermostabilized multivalent vaccines in a single vial platform presentation. Collaborators at UHM describe the potent efficacy of vaccine candidates protecting against three life-threatening filoviruses, Zaire ebolavirus, Sudan ebolavirus and Marburg Marburgvirus in an article titled "Recombinant Protein Filovirus Vaccines Protect Cynomolgus Macaques from Ebola, Sudan, and Marburg Viruses", published in Frontiers in Immunology.
--June 10, 2021: Soligenix Receives Pediatric Investigational Plan Waiver For HyBryte In CTCL From European Medicines Agency.
Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has received a Pediatric Investigation Plan (PIP) waiver from the European Medicines Agency (EMA) for HyBryte (SGX301 or hypericin), which has recently and successfully concluded a Phase 3, pivotal clinical study for the treatment of early stage cutaneous T-cell lymphoma (CTCL).
-- December 2021: SNGX:”A number of hedge funds have recently added to or reduced their stakes in SNGX. Geode Capital Management LLC raised its stake in shares of Soligenix by 11.7% in the second quarter. Geode Capital Management LLC now owns 244,085 shares of the biopharmaceutical company’s stock valued at $270,000 after acquiring an additional 25,549 shares during the last quarter. Millennium Management LLC acquired a new position in shares of Soligenix during the 3rd quarter worth about $31,000. State Street Corp bought a new stake in shares of Soligenix in the 2nd quarter valued at about $50,000. Goldman Sachs Group Inc. bought a new stake in shares of Soligenix in the 2nd quarter valued at about $60,000. Finally, Two Sigma Securities LLC bought a new stake in shares of Soligenix in the 3rd quarter valued at about $62,000. 10.31% of the stock is currently owned by institutional investors and hedge funds.”
SNGX has 6 others in later 50% half of pipeline/progress. Besides Hybryte delay they have: SGX942, SGX203, SGX 201, Rivax, SGX943, and ThermoVax) not to mention $29m in CASH + additional $865,000 grant in July ++ current $90mm sales with forecast of $700mm !
Soligenix Pipeline: https://www.soligenix.com/pipeline-programs/
GLTA
...
....
.....
Recent SNGX News
- Join Soligenix's Exclusive Live Investor Webinar and Q&A Session on September 18, 2024 • PR Newswire (US) • 09/16/2024 11:30:00 AM
- Soligenix Receives European Patent for Improved Production of Synthetic Hypericin • PR Newswire (US) • 09/03/2024 11:30:00 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 08/16/2024 08:19:57 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/16/2024 08:13:45 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 08/09/2024 08:09:14 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 08/09/2024 08:07:35 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2024 08:05:32 PM
- Soligenix Announces Recent Accomplishments And Second Quarter 2024 Financial Results • PR Newswire (US) • 08/09/2024 11:30:00 AM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 08/05/2024 04:15:07 AM
- Strong Clinical Momentum for Soligenix's HyBryte™ in Treating Cutaneous T-Cell Lymphoma; PCG Digital Exclusive with Dr. Brian Poligone • GlobeNewswire Inc. • 08/01/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/25/2024 11:30:14 AM
- PRISM MarketView Features Q&A with Dr. Ellen Kim: Soligenix's HyBryte™— Lighting the Way Towards Commercial Success with Promising FLASH Study Results • GlobeNewswire Inc. • 07/15/2024 02:16:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/09/2024 05:28:54 PM
- Expanded HyBryte™ Treatment Demonstrating Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma • PR Newswire (US) • 07/09/2024 11:30:00 AM
- Soligenix Announces Positive Clinical Results from a Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma • PR Newswire (US) • 06/25/2024 11:30:00 AM
- A Comparison of Vaccine Technologies to be Presented at the ASM Microbe Conference • PR Newswire (US) • 06/14/2024 11:30:00 AM
- Setting the Stage for Success: PRISM MarketView Highlights Soligenix's Promising HyBryte™ Replication Trial • GlobeNewswire Inc. • 06/05/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/31/2024 12:00:25 PM
- Soligenix Announces Reverse Stock Split • PR Newswire (US) • 05/31/2024 11:30:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/29/2024 08:05:07 PM
- Soligenix Encourages Stockholders to Vote their Shares at the Annual Meeting • PR Newswire (US) • 05/29/2024 11:30:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/28/2024 08:08:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/24/2024 08:05:27 PM
- Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting • PR Newswire (US) • 05/24/2024 11:30:00 AM
- Soligenix Encourages Stockholders to Vote "FOR" Reverse Stock Split • PR Newswire (US) • 05/23/2024 11:30:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM